Paris, France

Patrick Benoit

USPTO Granted Patents = 11 


Average Co-Inventor Count = 5.2

ph-index = 7

Forward Citations = 139(Granted Patents)


Company Filing History:


Years Active: 1998-2010

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: The Innovations of Patrick Benoit

Introduction

Patrick Benoit is a notable inventor based in Paris, France. He has made significant contributions to the field of biotechnology, particularly in the study and treatment of Alzheimer's disease. With a total of 11 patents to his name, Benoit has established himself as a key figure in his area of expertise.

Latest Patents

Among his latest patents, one invention focuses on transgenic animals exhibiting major disorders related to Alzheimer's disease. This invention relates to nonhuman transgenic animals that can be utilized for demonstrating compounds intended for the treatment of Alzheimer's disease. Another significant patent involves monoclonal antibodies against the interferon receptor, which possess neutralizing activity against type I interferon. This invention is characterized by a monoclonal antibody directed against the human interferon class I receptor (IFN-R), which recognizes the extracellular domain of the human IFN-R and has a neutralizing capacity against the biological properties of human type I-IFN. It also concerns their use for diagnostic purposes.

Career Highlights

Throughout his career, Patrick Benoit has worked with prominent companies such as Rhone-Poulenc Rorer S.A. and Medarex Inc. His work in these organizations has contributed to advancements in medical research and therapeutic development.

Collaborations

Benoit has collaborated with several notable individuals in his field, including Patrice Denefle and Francois Meyer. These collaborations have further enhanced his research and innovation efforts.

Conclusion

Patrick Benoit is a distinguished inventor whose work has significantly impacted the field of biotechnology. His innovative patents and collaborations reflect his commitment to advancing medical research and treatment options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…